US Markets

Elanco Animal Health wins approval to buy Bayer unit

Credit: REUTERS/Wolfgang Rattay

Elanco Animal Health has won U.S. antitrust approval to buy Bayer AG's animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

WASHINGTON, July 15 (Reuters) - Elanco Animal Health ELAN.N has won U.S. antitrust approval to buy Bayer AG's BAYGn.DE animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

The deal was valued at $7.6 billion when it was announced in August 2019.

To win antitrust approval, the FTC said it required the companies to sell assets related to oral treatments to kill fleas on dogs, an inflammation of dogs' inner ears and some pour-on cattle insecticides which control multiple insects.

(Reporting by Diane Bartz Editing by Chizu Nomiyama)

((Diane.Bartz@thomsonreuters.com; 1 202 898 8313;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ELAN

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More